home.aspx
 
EVENTS

THE 2021 CLINICAL DISCLOSURE VIRTUAL
THE 2021 CLINICAL DISCLOSURE VIRTUAL
May 11-12, 2021
Sophisticated and fully interactive conference experience, leverage best practices, networking and on-demand sessions will be available in one place, at the touch of a button.

Discover how Clinical Data Disclosure, Transparency & Plain Language Summaries Virtual Platform will elev...

Pharma Manufacturing Automation 2021
PHARMA MANUFACTURING AUTOMATION 2021
May 18-19, 2021
As the use of the robotics in the pharmaceutical manufacturing industry increases rapidly, it’s important to consider the benefits of the latest technologies for manufacturers, researchers and scientists. The advantages include greater speed and accuracy, more flexibility and more reliability ...

Amgen

SHARESHARESHARE
Amgen is committed to unlocking the potential of biology for patients suffering from serious illnesses by discovering, developing, manufacturing and delivering innovative human therapeutics. This approach begins by using tools like advanced human genetics to unravel the complexities of disease and understand the fundamentals of human biology.
SHARESHARESHARE

RELATED NEWS


Last June, 10 major pharmaceutical companies — Amgen, Astellas, AstraZeneca, Bayer, Boehringer Ingelheim, GSK, Institut De Recherches Servier, Janssen, Merck, and Novartis — inked an agreement to build a shared platform called MELLODDY (Machine Learning Ledger Orchestration for Drug Discovery). In partnership with Nvidia, Owkin, and other tech partners, the group sought to leverage techniques like federated learning to collectively train AI on datasets without having to share any pro...
VENTUREBEAT
READ MORE

The drug industry has come together in unprecedented collaborative efforts to tackle COVID-19. Now, as part of an R&D alliance, three big drugmakers are running a joint clinical trial to see whether their products can improve outcomes for severely ill patients. A recently launched clinical program, dubbed I-SPY, will test Amgen’s psoriasis med Otezla, Takeda’s hereditary angioedema therapy Firazyr and AbbVie’s experimental nonalcoholic steatohepatitis drug cenicriviroc to s...
FIERCEPHARMA
READ MORE

Novartis AG (NOVN.S) and Bayer AG (BAYGn.DE) are among nearly 30 drugmakers that have taken steps to raise the U.S. prices of their medicines in January, ending a self-declared halt to increases made by a pharma industry under pressure from the Trump administration, according to documents seen by Reuters. Other drugmakers set to raise prices at the start of 2019 include Allergan Plc (AGN.N), GlaxoSmithKline Plc (GSK.L), Amgen Inc (AMGN.O), AstraZeneca Plc (AZN.L) and Biogen Inc (BIIB.O), the doc...

READ MORE

Amgen and Allergan have filed for approval of their biosimilar version of Roche’s CD20-targeting drug Rituxan with the FDA, vying to become the third copycat version of the blockbuster drug approved in the US. If approved, Amgen and Allergan’s biosimilar – called ABP 798 – will follow in the footsteps of Teva/Celltrion’s Truxima and Pfizer’s Ruxience, approved by the FDA in 2018 and earlier in 2019, respectively. A fourth potential rival developed by Novartis ...

READ MORE

Sanofi and Regeneron's next-gen cholesterol drug Praluent never lived up to early expectations, and its price tag was at least partly to blame. The cost petrified payers. Even before it—and its fellow PSCK9 med from Amgen—won FDA approval in 2015, pharmacy benefit managers (PBMs) rang alarms about the hundreds of billions the new PCSK9 class could cost the healthcare system. But payers themselves weren't the only ones calling out costs after the drugs launched with stickers o...

READ MORE

Looks like Amgen might not be buying Alexion Pharmaceuticals after all. Instead, its beefing up in psoriasis, where it already sells blockbuster TNF inhibitor Enbrel. Amgen Monday said it will take in Celgenes Otezla for 13.4 billion dollars in cash, a purchase that could help Bristol-Myers Squibb move along with its planned acquisition of Celgene for 74 billion dollars, per an agreement with U.S. antitrust authorities. The dollar amount easily dwarfs some recent biopharma deals for entire compa...

READ MORE

FibroGen has not even filed its AstraZeneca-partnered oral anemia drug roxadustat for U.S. approval. But the collaborators have already scored their second nod for the blockbuster hopeful in China. Last December, the pair made a rare if not only case out of roxadustat by racking up its first-in-class approval in China before any other country. At that time, Chinese authorities greenlighted the drug for patients on dialysis. With this second approval, it’s now allowed to treat the larger no...

READ MORE

Another Alzheimers disease drug has been axed after Novartis, Amgen and the Banner Alzheimers Institute decided to end two pivotal studies involving a medicine targeting BACE. The organisations have ended development of the BACE1 (beta secretase 1) inhibitor CNP520 – or umibecestat – which was in two phase 2/3 studies in the Alzheimer’s Prevention Initiative Generation Program. They made the decision after assessment of unblinded data during a regular pre-planned review identif...

READ MORE

Sales of Eli Lilly’s migraine and cluster headache med Emgality have lagged behind competitors from Amgen and Novartis and Teva Pharmaceutical. And in its push to bring payers on board, Lilly is deploying a full-court press with some new patient data. Just 5% of frequent migraine sufferers who seek emergency care for their symptoms are treated with a migraine prevention medication like Emgality, according to data from Lilly’s observational study of 20,000 trial patients, dubbed Overc...

READ MORE

The proposal seeks to shame biopharma companies into lowering their prices through public pressure. HHS published the rule in May, arguing that price disclosure would allow Medicare and Medicaid beneficiaries to make informed decisions about their own out-of-pocket costs. It was due to go into effect today. Merck & Co., Eli Lilly and Amgen, along with the National Association of Advertisers, sued HHS, claiming violations of First Amendment free speech rights, along with challenging HHS autho...

READ MORE

EVENTS

THE 2021 CLINICAL DISCLOSURE VIRTUAL
THE 2021 CLINICAL DISCLOSURE VIRTUAL
May 11-12, 2021
Sophisticated and fully interactive conference experience, leverage best practices, networking and on-demand sessions will be available in one place, at the touch of a button.

Discover how Clinical Data Disclosure, Transparency & Plain Language Summaries Virtual Platform will elev...

Pharma Manufacturing Automation 2021
PHARMA MANUFACTURING AUTOMATION 2021
May 18-19, 2021
As the use of the robotics in the pharmaceutical manufacturing industry increases rapidly, it’s important to consider the benefits of the latest technologies for manufacturers, researchers and scientists. The advantages include greater speed and accuracy, more flexibility and more reliability ...